Survival of Hospitalized Patients With Concurrent COVID-19 and Hematological Malignancies

[JT_Marlin]

TAKE-HOME MESSAGE

This retrospective cohort study evaluated outcomes in 34 patients with COVID-19 infection and concurrent hematological malignancies. Patients were stratified into survivors (n=23) and non-survivors (n=11) for comparative analyses. On review of baseline clinical and laboratory parameters at illness onset or on admission, only procalcitonin levels were significantly higher in non-survivors than survivors. The development of acute respiratory distress syndrome, an ECOG performance status ≥2, and qSOFA score ≥2 were associated with shorter survival.

This cohort study describes the presenting clinical and laboratory characteristics in a diverse group of hematological malignancy patients admitted with COVID-19 infection and provides data on outcomes in this vulnerable patient population.

– Curtis Lachowiez, MD

The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).

practiceupdate.com/C/100506...

(Could only attach one photo of the table data, but essentially there were 3 PV patients of the n=34....none of them made it :(....though they were 71, 85, and 94).

[hunter5582]

Thanks for posting. I would suspect that age may have been more the issue than PV pers se. 71-85-94 would be considered high-risk no matter what other conditions the person had. Takeaway from the MPN-COVID webinar yesterday would be that if you have been symptomatic due to a MPN (e.g. thrombosis) then COVID could present an additive effect - increasing risk. If not symptomatic - risk is still unknown.

Hopefully we will all know more soon. Unfortunately, the data will come from people with MPNs who get COVID. Would rather not be part of that database.

ALl the best.